Compare iShares International Treasury Bond ETF (IGOV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Moderna, Inc. — how do they compare? iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 60.5× iShares International Treasury Bond ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Moderna, Inc. for 59 Days on average.
| IGOV | MRNA | |
|---|---|---|
Market Cap | $1.30B | $78.65B |
Volume | 693,740 | 37,373,437 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $225.00 |
52-Week Low | $39.65 | $22.36 |
Typical Hold Time | 92 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.73, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages heavily skewed to sell signals. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights a rising bond yield environment, which may influence investor allocation decisions away from equities.
The outlook is cautious due to the bearish technical posture and lack of clear fundamental data. Investment opportunity hinges on future financial disclosures confirming business strength. Primary risks include market volatility from macroeconomic shifts in interest rates and potential underperformance if the company's fundamentals are weak.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
